OncoLife IVMN

dickson chemist

ONCOLIFE-IVMN is an unlicensed medicine, manufactured on an individual patient basis at the request of a prescriber.

ONCOLIFE-IVMN comes in 10mg/1ml and 20mg/1ml suspensions, for administration via oral route only. The active drug is Ivermectin.

Ivermectin is being investigated as an immunomodulator and metabolic pathway modifying drug in neoplastic and some chronic inflammatory conditions.

USAGE of Oncolife IVM

ONCOLIFE-IVMN may be useful as an alternative therapy in an increasing number of neoplastic and inflammatory conditions, determined after consultation with an appropriate health care practitioner.

Ivermectin, the active drug, is licensed world-wide as an anthelmintic (a class of medicine used to treat parasitic infections). In post marketing surveilance, it was found to have a wide spectrum of actions far exceeding the anti-parasitic license.

ONCOLIFE-IVMN has compulsory reporting, so in order to obtain this product a consultation must be completed with a suitably qualified prescriber.

ONCOLIFE-IVMN is usually taken daily at a dose calculated from your body weight, and not exceeding 0.5mg/kg of body weight. *It should not be taken for longer than 4 weeks continuously*.

WARNINGS AND PRECAUTIONS

BEFORE you use ONCOLIFE-IVMN talk to your prescriber if you:

- **have previously had a reaction to ivermectin**
- **are taking any blood thinning products containing warfarin or coumadins**

INTERACTIONS WTH THIS PRODUCT

If you go into hospital you must tell the doctors all the medicines you are taking. This includes ONCOLIFE-IVMN.

Some drugs interact with Ivermectin . Therefore it is important that prior to taking Ivermectin you tell your prescriber if you are taking potent liver enzyme modifiers:

- clarithromycin, diltiazem, erythromycin, itraconazole, ketoconazole, ritonavir, and verapamil (and similar) inhibit the enzymes that break down ivermectin so the dose of Ivermectin should be **halved** during therapy with these drugs.

- phenobarbital, phenytoin and rifampicin are potent enzyme inducers - meaning that therapy with Ivermectin may be less effective (similar drugs also exist). Clinical importance unknown.

- warfarin, and coumadin based blood thinners may react unpredictably when taken with ONCOLIFE-IVMN. Taking both together is contraindicated unless daily INR readings are taken during therapy.

PROPER USE OF THIS PRODUCT

ONCOLIFE-IVMN is supplied as a pharmaceutical suspension. A measuring syringe is provided. The dose prescribed should be drawn up into the syringe and taken orally. The product should not be diluted or mixed with anything before being taken.

ONCOLIFE-IVMN may settle on prolonged storage so shake the bottle before taking a dose.

Markings are clearly labelled on the side of the oral syringe - dosing is in millilitres.

If you forget to take a dose, take the next dose and carry on a before, do NOT double your dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Ivermectin has a low side effect profile, and is generally well tolerated. As with all medicines individuals may experience side effects. These include, most commonly:

- dizziness
- loss of appetite
- nausea
- vomiting
- stomach pain or bloating
- diarrhea
- constipation
- weakness
- uncontrollable shaking of a part of the body
- chest discomfort

If these side effects do not resolve after taking ONCOLIFE-IVMN for a few weeks, speak to your doctor or pharmacist.

Some people taking ONCOLIFE-IVM may develop a reaction called a Herxheimer. This involves a high temperature and rigours within 7 days of starting. This should be treated with standard anti-pyrexics and ONCOLIFE-IVM stopped until symptoms resolve.

INGREDIENTS AND STORAGE

ONCOLIFE-IVMN is formulated to be hypo-allergenic. The suspension contains Ivermectin at 10mg/1ml or 20mg/1ml and a base which contains water, carbomer and propylene glycol.

Storage is for 30 days after receipt at room temperature not exceeding 25 degrees centigrade. **Do not refrigerate or freeze.**

Any unused suspension should not be disposed of in domestic drains and *must be returned to a pharmacy for incineration*. Do not pour this medicine down the sink or toilet at it could severely damage aquatic life.

KEEP OUT OF SIGHT AND REACH OF CHILDREN
STORE IN A SECURE PLACE
DO NOT GIVE YOUR ONCOLIFE-IVM TO ANYONE ELSE

MORE INFORMATION

ONCOLIFE-IVMN is manufactured by :
Rokshaw Laboratories
5a Rivergreen Industrial Estate Sunderland
SR4 6AD (MS43743)

Regulatory compliance assured by:
Thistle Pharma
10 Ardross Street, Inverness IV3 5NS

and supplied exclusively by:
Dickson Chemist 35 Mitchell Arcade, Rutherglen, G73 2LS 0141 404 6545

REFERENCES

1. Crump, A. Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations. J Antibiot 70, 495–505 (2017). https://doi.org/10.1038/ja.2017.11
2. Lee DE, Kang HW, Kim SY, Kim MJ, Jeong JW, Hong WC, Fang S, Kim HS, Lee YS, Kim HJ, Park JS. Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction. Front Pharmacol. 2022 Aug 26;13:934746. doi: 10.3389/fphar.2022.934746. PMID: 36091811; PMCID: PMC9459089.
3. Markowska A, Kaysiewicz J, Markowska J, Huczyński A. Doxycycline, salinomycin, monensin and ivermectin repositioned as cancer drugs. Bioorg Med Chem Lett. 2019 Jul 1;29(13):1549-1554. doi: 10.1016/j.bmcl.2019.04.045. Epub 2019 Apr 27. PMID: 31054863.
4. Tang M, Hu X, Wang Y, Yao X, Zhang W, Yu C, Cheng F, Li J, Fang Q. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res. 2021 Jan;163:105207. doi: 10.1016/j.phrs.2020.105207. Epub 2020 Sep 21. PMID: 32971268; PMCID: PMC7505114.

PRESCRIBING INFORMATION

ONCOLIFE-IVMN should be prescribed by brand in 10mg/1ml or 20mg/1ml strength.
Dose is calculated as 0.25mg/kg body weight once daily for 2 weeks, titrating to a maximum of 0.5mg/kg bodyweight. Exposure to drug should be limited to a maximum of 4 weeks with 4 weeks break between dosing.